Zollinger-Ellison Syndrome (Gastrinoma) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/2njhxw/zollingerellison) has announced the addition of the "Zollinger-Ellison Syndrome (Gastrinoma)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016" report to their offering.

Zollinger-Ellison Syndrome (Gastrinoma)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

A key objective of the Zollinger-Ellison Syndrome (Gastrinoma) Report is to understand the market and pipeline status of the drugs around the Zollinger-Ellison Syndrome (Gastrinoma) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies.

The Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Zollinger-Ellison Syndrome (Gastrinoma). While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia, specifically China and India.

Key Topics Covered:

1. Indication Overview

2. Market Drugs Landscape

2.1 Marketed Drugs

2.2 Marketed Details of Drugs by Application Type

2.3 Marketed Details of Drugs (NDA) by Marketing Status

2.4 Marketed Details of Drugs by Patent Expiration Timeline

3. Global API Manufacturers Assessment

3.1 API Manufacturers by United States Drug Master File (US DMF) Status

3.2 API Manufacturers by US DMF Status (Drug Specific)

3.3 API Manufacturers in Europe by Country

3.4 API Manufacturers in India by State

3.5 API Manufacturers in China by Province

3.6 Marketed Details of Approved Drugs by Geography

4. Phase III Drugs Landscape

4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs

4.2 API Manufacturers by US DMF Status (Drug Specific)

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Zollinger-Ellison Syndrome (Gastrinoma)

6.1 Drug Name

6.1.1 Drug Description

6.1.2 Global Active Pharmaceutical Manufacturers for Drug

6.1.3 Approval Status of Drug

6.1.4 Patent and Exclusivity Details for Drug

6.1.5 Company Profile and Financials

7. Phase III Drugs for Zollinger-Ellison Syndrome (Gastrinoma)

7.1 Drug Name

7.1.1 Drug Description

7.1.2 United States Drug Master File (DMF)

8. Discontinued Drugs for Zollinger-Ellison Syndrome (Gastrinoma)

9. Appendix

10. Methodology

For more information visit http://www.researchandmarkets.com/research/2njhxw/zollingerellison.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals